Severe Asthma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - GSK, AstraZeneca, Avillion, 4D Pharma, Novartis, Avalo Therapeutics, Biosion

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Severe Asthma pipeline constitutes key companies continuously working towards developing Severe Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Severe Asthma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Severe Asthma Market.

The Severe Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Severe Asthma Pipeline Report: https://www.delveinsight.com/report-store/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Severe Asthma treatment therapies with a considerable amount of success over the years. Severe Asthma Key players such as - GSK, AstraZeneca, Avillion, 4D Pharma, Novartis, Avalo Therapeutics, Biosion, and others, are developing therapies for the Severe Asthma treatment
• Severe Asthma Emerging therapies such as - GSK3511294 (depemokimab), PT027, PT010, MRx4DP0004, CSJ117 (Ecleralimab), AVTX-002, BSI-045B, and others are expected to have a significant impact on the Severe Asthma market in the coming years.
• In August 2021, the U.S. Food and Drug Administration (FDA) approved tezepelumab (brand name: Tepezza) for the treatment of patients with severe, uncontrolled asthma.
• The TERRANOVA study, which was published in The Lancet Respiratory Medicine in February 2021, demonstrated that treatment with the biologic medication dupilumab significantly reduced severe asthma exacerbations in patients with uncontrolled asthma and high levels of type 2 inflammation.

Severe Asthma Overview
Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodeling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction.

Get a Free Sample PDF Report to know more about Severe Asthma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Severe Asthma Drugs Under Different Phases of Clinical Development Include:
• GSK3511294 (depemokimab): GSK
• PT027: AstraZeneca/Avillion
• PT010: AstraZeneca
• MRx4DP0004: 4D Pharma
• CSJ117 (Ecleralimab): Novartis
• AVTX-002: Avalo Therapeutics
• BSI-045B: Biosion

Route of Administration
Severe Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Severe Asthma Pipeline Therapeutics Assessment
• Severe Asthma Assessment by Product Type
• Severe Asthma By Stage and Product Type
• Severe Asthma Assessment by Route of Administration
• Severe Asthma By Stage and Route of Administration
• Severe Asthma Assessment by Molecule Type
• Severe Asthma by Stage and Molecule Type

DelveInsight's Severe Asthma Report covers around products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Download Sample PDF Report to know more about Severe Asthma drugs and therapies
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Severe Asthma Therapeutics Market include:
Key companies developing therapies for Severe Asthma treatment are - Adamis Pharmaceuticals Corporation, Aerocrine (Circassia), ALK-Abello A/S, Amphastar Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, Dimerix, GlaxoSmithKline, Innoviva, Lallemand Pharma International, Merck, Mereo BioPharma Group plc, MundiPharma, Novartis, Pulmatrix, Respiratorius AB, Roche, and others

Severe Asthma Pipeline Analysis:
The Severe Asthma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Severe Asthma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Severe Asthma Treatment.
• Severe Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Severe Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Severe Asthma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Severe Asthma product details are provided in the report. Download the Severe Asthma pipeline report to learn more about the emerging Severe Asthma therapies at:
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Severe Asthma Pipeline Market Drivers
• Robust Severe Asthma pipeline
• Improving diagnostic approach
• Increasing demand for personalized therapies
• Increasing Prevalent cases of Severe Asthma

Severe Asthma Pipeline Market Barriers
• High cost of Severe Asthma treatment
• Limitations in Severe Asthma diagnosis
• Incorrect inhaler techniques
• Poor Adherence to treatment

Scope of Severe Asthma Pipeline Drug Insight
• Coverage: Global
• Key Severe Asthma Companies: GSK, AstraZeneca, Avillion, 4D Pharma, Novartis, Avalo Therapeutics, Biosion, and others
• Key Severe Asthma Therapies: GSK3511294 (depemokimab), PT027, PT010, MRx4DP0004, CSJ117 (Ecleralimab), AVTX-002, BSI-045B, and others
• Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies
• Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers

Request for Sample PDF Report for Severe Asthma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Severe Asthma Report Introduction
2 Severe Asthma Executive Summary
3 Severe Asthma Overview
4 Severe Asthma- Analytical Perspective In-depth Commercial Assessment
5 Severe Asthma Pipeline Therapeutics
6 Severe Asthma Late Stage Products (Phase II/III)
7 Severe Asthma Mid Stage Products (Phase II)
8 Severe Asthma Early Stage Products (Phase I)
9 Severe Asthma Preclinical Stage Products
10 Severe Asthma Therapeutics Assessment
11 Severe Asthma Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Severe Asthma Key Companies
14 Severe Asthma Key Products
15 Severe Asthma Unmet Needs
16 Severe Asthma Market Drivers and Barriers
17 Severe Asthma Future Perspectives and Conclusion
18 Severe Asthma Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.